Journal of Pharmaceutical Sciences 1994-02-01

Metabolites of ebrotidine, a new H2-receptor antagonist, in human urine.

E Rozman, M T Galcerán, L Anglada, C Albet

Index: J. Pharm. Sci. 83(2) , 252-4, (1994)

Full Text: HTML

Abstract

Ebrotidine is a new H2-receptor antagonist which exhibits a remarkable ability for gastric mucosal protection. A preliminary metabolic pathway for this compound was proposed and the hypothetic metabolites were synthesized. The presence of ebrotidine and its metabolites ebrotidine S-oxide and 4-bromobenzenesulfonamide in human urine has been confirmed by HPLC separation and spectroscopic characterization of the collected fractions by FT-IR and 1H NMR. Ebrotidine S,S-dioxide has been identified by HPLC using diode-array detection.

Related Compounds

Related Articles:

Synthesis and biological evaluation of linear phenylethynylbenzenesulfonamide regioisomers as cyclooxygenase-1/-2 (COX-1/-2) inhibitors.

2006-08-01

[Bioorg. Med. Chem. 14(15) , 5259-65, (2006)]

Determination of ebrotidine metabolites in overlapping peaks from capillary zone electrophoresis using chemometric methods.

2001-01-01

[Electrophoresis 22(1) , 71-6, (2001)]

Combining NMR and molecular modelling in a drug delivery context: investigation of the multi-mode inclusion of a new NPY-5 antagonist bromobenzenesulfonamide into beta-cyclodextrin.

2004-01-15

[Bioorg. Med. Chem. 12(2) , 447-58, (2004)]

Preparation of novel cobalt (III) complexes with dithiocarbimates derived from sulfonamides. Oliveira MRL and Bellis VMD.

[Transit. Met. Chem. 24(2) , 127-130, (1999)]

More Articles...